SCHEMBL1103359

SCHEMBL1103359

c1ccc(-c2c3ccccc3c(-c3ccccc3-c3ccc4ccccc4c3)c3c2cnc2ccccc23)c(-c2ccc3ccccc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.48
DHFR P00374 1/20 0.40
KDM4E B2RXH2 2/20 0.40
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
GPR3 P46089 1/20 0.39
GSTP1 P09211 1/20 0.38
PDPK1 O15530 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103508 0.96 MET (0.47) METDHFRKDM4EHDAC4HDAC2
SCHEMBL1103567 0.95 MET (0.47) METDHFRKDM4EHDAC4HDAC2
SCHEMBL1103389 0.94 MET (0.46) METDHFRKDM4EHDAC4HDAC2
SCHEMBL1103368 0.92 MET (0.46) METDHFRKDM4EHDAC4HDAC2
SCHEMBL1103506 0.91 MET (0.43) METDHFRKDM4EGPR3PDPK1
SCHEMBL1103509 0.90 MET (0.42) METDHFRKDM4EGPR3PDPK1
SCHEMBL1103578 0.90 MET (0.47) METDHFRKDM4EHDAC4HDAC2
SCHEMBL1103514 0.88 MET (0.45) METDHFRKDM4EHDAC4HDAC2
SCHEMBL1103463 0.88 MET (0.41) METDHFRKDM4EGPR3GSTP1
SCHEMBL1103515 0.87 MET (0.42) METDHFRKDM4EHDAC4HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MET 4191/4885DHFR 3167/4885KDM4E 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.